Welcome to our dedicated page for ANI PHARMACEUTICALS SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANI PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANI PHARMACEUTICALS's regulatory disclosures and financial reporting.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold shares in a planned transaction. On July 2, 2026, he exercised a stock option for 3,313 shares of common stock at $49.51 per share and sold 3,313 shares in an open-market transaction at $86 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following these transactions, he directly holds 177,543 shares of ANI Pharmaceuticals common stock. The option had vested in four 25% installments on March 31 of 2018, 2019, 2020, and 2021 and carries an expiration date of March 30, 2027.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an open-market sale of 2,850 shares of common stock at a weighted average price of $84.12 per share. After the sale, he directly holds 177,543 shares, indicating that the transaction represents a small portion of his overall stake.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and occurred in multiple transactions at prices ranging from $83.39 to $84.63. Such plans are designed to allow insiders to sell shares over time according to preset instructions.
ANI Pharmaceuticals senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of Common Stock. The shares were sold at an average price of $82.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After this sale, Cook directly held 77,890 shares of ANI Pharmaceuticals common stock.
Thoma Jeanne reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Jeanne Thoma received a new equity grant. She was awarded 4,357 shares of ANI Pharmaceuticals common stock as a restricted stock award, with no cash paid per share. After this grant, she directly holds 27,762 common shares.
The restricted stock award will vest in full on May 21, 2027, meaning she will gain full ownership of these shares on that date if the vesting conditions are satisfied.
TANNENBAUM RENEE P reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Renee P. Tannenbaum received a grant of 4,357 shares of common stock as a restricted stock award on May 21, 2026. The award carries no purchase price and will vest in full on May 21, 2027, if conditions are met.
Following this compensation-related grant, Tannenbaum directly holds 29,514 shares of ANI Pharmaceuticals common stock. This is a routine equity award to a board member rather than an open-market transaction.
Pera Antonio R reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Antonio R. Pera received a grant of 4,357 shares of Common Stock as a restricted stock award. The award was granted at no cash cost to him and is part of his equity compensation.
The restricted shares are scheduled to vest in full on May 21, 2027, meaning they must be held until that date before becoming fully transferable. Following this grant, Pera directly holds a total of 27,017 shares of ANI Pharmaceuticals Common Stock.
Leonard Matthew J reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Matthew J. Leonard received a grant of 4,357 shares of common stock as a restricted stock award. The award was granted at no cash cost per share and is part of his equity-based compensation. These restricted shares will vest in full on May 21, 2027, meaning he must remain eligible through that date to receive them outright. After this grant, Leonard directly holds a total of 11,221 shares of ANI Pharmaceuticals common stock, indicating this is a relatively small, routine compensation-related award rather than a market purchase or sale.
ANI Pharmaceuticals director Thomas Haughey reported both a stock grant and a share sale. On May 21, 2026, he acquired 4,357 shares of Common Stock as a restricted stock award that will vest in full on May 21, 2027. On June 8, 2026, he sold 2,000 Common Stock shares in an open-market transaction at $80.88 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026. After these transactions, he directly holds 38,878 Common Stock shares.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an option exercise and share sale. He exercised stock options to acquire 3,312 shares of common stock at $49.51 per share, then sold 3,312 shares in an open-market transaction at $80.00 per share. The transactions were completed under a pre-arranged Rule 10b5-1 trading plan. After these trades, Carey directly owns 180,393 shares of ANI Pharmaceuticals common stock.